Cargando…

Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?

Mostrar otras versiones (1)

Detalles Bibliográficos
Autor principal:	Keikha, Masoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212853/ https://www.ncbi.nlm.nih.gov/pubmed/35757084 http://dx.doi.org/10.1016/j.vacun.2022.06.001

Ejemplares similares

Recommendation of a fourth SARS-CoV-2 vaccine dosage in vulnerable individuals, yes or not?
por: Keikha, Masoud
Publicado: (2022)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned?
por: Roohani, Jalil, et al.
Publicado: (2022)

A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients
por: Masset, Christophe, et al.
Publicado: (2022)

Even after the fourth dose of a SARS-CoV-2 vaccine neurological complications may develop
por: Finsterer, Josef
Publicado: (2023)

Antibody Titers After a Third and Fourth SARS-CoV-2 Vaccine Dose in Bizen City, Japan
por: Kadowaki, Tomoka, et al.
Publicado: (2023)

Compulsary SARS-CoV-2 (booster-) vaccination in healthcare facilities can not replace personal protection measures while dealing with vulnerable individuals
por: Schildgen, Verena, et al.
Publicado: (2022)

Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies
por: Ghazvini, K., et al.
Publicado: (2021)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2
por: Roussel, Y., et al.
Publicado: (2020)

Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023)

Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine
por: Xu, Xingli, et al.
Publicado: (2022)

Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated individuals with no history of infection
por: Favresse, Julien, et al.
Publicado: (2023)

The global reemergence of human Monkeypox; is mass vaccination essential?
por: Namdar, Ali Beheshti, et al.
Publicado: (2022)

SARS-CoV-2 and the myths about vaccination()
por: Travezaño-Cabrera, Aaron, et al.
Publicado: (2021)

Immunophenotyping of SARS-CoV-2 and vaccine design
por: Cimolai, Nevio
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine: Correspondence
por: Sriwijitalai, Won, et al.
Publicado: (2023)

The Russo-Ukrainian war crisis and vaccination of Ukrainian refugees as an urgent need
por: Namdar, Ali Beheshti, et al.
Publicado: (2022)

Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals
por: Boccuto, Adele, et al.
Publicado: (2021)

Autoimmune diseases related to post-SARS-CoV-2 vaccination; a rheumatology perspective
por: Dadgar, Farhad, et al.
Publicado: (2023)

SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC)
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

Two SARS-CoV-2 serology assays detect antibodies in the sera of individuals diagnosed with SARS-CoV-2 Omicron variant
por: Conklin, Justin, et al.
Publicado: (2022)

Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection
por: Kang, Sung Woon, et al.
Publicado: (2022)

Commentary: SARS-CoV-2 vaccines and cancer patients
por: Corti, C., et al.
Publicado: (2021)

Impact of SARS-CoV-2 vaccines on the nervous system
por: Scorza, Fulvio Alexandre, et al.
Publicado: (2022)

Graves’ disease following SARS-CoV-2 vaccination
por: Sriphrapradang, Chutintorn, et al.
Publicado: (2021)

Vaccination of susceptible animals against SARS-CoV-2
por: Xiang, Bin, et al.
Publicado: (2022)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccinations can trigger polyradiculitis
por: Finsterer, Josef, et al.
Publicado: (2022)

Subacute thyroiditis and different SARS-CoV-2 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

SARS-CoV-2 antibody response eight months after vaccination with mRNA vaccines. Influence of prior SARS-CoV-2 exposure
por: García-Cruces-Méndez, Jesús Fernando, et al.
Publicado: (2022)

Optic neuritis associated with COVID-19-related vaccines
por: Keikha, Masoud, et al.
Publicado: (2023)

Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual
por: Ogai, Asuka, et al.
Publicado: (2021)

Longer Intervals before Vaccination Increase Spike Antibody Titers in Individuals Previously Infected with SARS-CoV-2
por: Bi, Xiuqiong, et al.
Publicado: (2022)

Non-epileptic myoclonus status can be due to both SARS-CoV-2 infection and SARS-CoV-2 vaccination
por: Finsterer, Josef
Publicado: (2023)

SARS-CoV-2: a general recommendation to adhere to government regulations cannot be evidence-based
por: Kampf, G., et al.
Publicado: (2021)

Physical activity and mobile applications, recommendations for remote workers during the SARS-CoV-2 pandemic
por: Cruz-Ausejo, Liliana, et al.
Publicado: (2021)

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab
por: Khayat-Khoei, Mahsa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n4qqthh9vpeg941j2e1g00vtv6